What is the ATP III?

What is the ATP III?

The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) constitutes the National Cholesterol Education Program’s (NCEP’s) updated clinical guidelines for cholesterol testing and manage- ment.

What is ACC Aha?

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health.

What is ATP IV?

Appendix D.: Target Lipid Recommendations (ATP-IV) Non-HDL-C is calculated as total cholesterol minus HDL-C . The addition of non- HDL-C to the Lipid Panel reflects the recognition of this calculated value as a predictive factor in cardiovascular disease based on the National Cholesterol Education III studies.

What is the HDL cholesterol?

HDL (high-density lipoprotein), or “good” cholesterol, absorbs cholesterol and carries it back to the liver. The liver then flushes it from the body. High levels of HDL cholesterol can lower your risk for heart disease and stroke.

What is EF in echocardiogram?

Ejection fraction is a measurement of the percentage of blood leaving your heart each time it squeezes (contracts).

What are the ATP IV guidelines?

The ATP-IV component of the guideline would address following three critical areas: 1) Evidence supporting LDL-C for secondary prevention; 2) Primary prevention of LDL; and 3) Efficacy and safety of major cholesterol drugs.

What do the new ATP III guidelines for LDL-C levels tell us?

The new guidelines do not provide ample guidance on evaluating and monitoring efficacy of therapy. ATP III and its 2005 update 3 set a goal for LDL-C at < 100 mg/dL for high-risk patients, especially those with established ASCVD. Patients with diabetes and a 10-year risk greater than 20% further counted as high-risk patients.

What are the ATP III and ACC/AHA guidelines on statin drug therapy?

Both ATP III and ACC/AHA guidelines carried out 10-year risk assessment to guide drug therapy. ATP III recommended consideration of drug therapy when 10-year risk for CHD was ≥ 10%. ACC/AHA set a threshold for statin drugs at 7.5% for ASCVD. Even ≥5% risk was considered a therapeutic option for statin therapy.

What do ATP III and ACC/AHA guidelines tell us about lifestyle intervention?

Both ATP III and ACC/AHA guidelines emphasize the value of lifestyle intervention. An interesting aspect of the ACC/AHA guidelines is that lifestyle is promoted without RCT evidence. In so doing, the new guideline panel broke their own evidence-based rules. Seemingly, these rules are applied only to drug therapy.

Do accacc/AHA guidelines ignore the role of LDL cholesterol?

ACC/AHA guidelines largely disregard any role for LDL because of their focus on the efficacy of particular drugs per se.